2026全球畅销药封神榜,都有谁?2026年畅销药战场,风云诡谲,格局重塑。肿瘤领域早已不是唯一焦点,C位悄然易主;如今已是GLP-1与自身免疫两大战役并驾齐驱,主宰着这场没有硝烟的战争。最为惨烈的厮杀莫过于GLP-1赛道的双姝对决。 礼来 与诺和诺德一招一式,皆中命门。礼来的替尔泊肽凭借365亿美元总销售额与121%的狂飙增速,正式登顶新一代药王宝座;而司美格鲁肽虽以361亿美元紧随其后,但面对...
Source Link2026全球畅销药封神榜,都有谁?2026年畅销药战场,风云诡谲,格局重塑。肿瘤领域早已不是唯一焦点,C位悄然易主;如今已是GLP-1与自身免疫两大战役并驾齐驱,主宰着这场没有硝烟的战争。最为惨烈的厮杀莫过于GLP-1赛道的双姝对决。 礼来 与诺和诺德一招一式,皆中命门。礼来的替尔泊肽凭借365亿美元总销售额与121%的狂飙增速,正式登顶新一代药王宝座;而司美格鲁肽虽以361亿美元紧随其后,但面对...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.